Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
GLP-1 drugs like semaglutide and tirzepatide — best known for treating diabetes and obesity — are showing a consistent signal for reducing alcohol-related hospitalizations and substance use disorder outcomes. Multiple large observational studies suggest these medications may blunt cravings across alcohol, opioids, nicotine, and more. Experts say randomized controlled trials are urgently needed to confirm the findings.
GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are best known for managing diabetes and obesity — but a growing body of research suggests they may also reduce addiction-related harms. Across four target trials involving nearly 48,000 adults with type 2 diabetes, obesity, or alcohol use disorder (AUD), semaglutide and tirzepatide were consistently associated with lower rates of alcohol-related hospitalizations compared to standard medications. A separate study of 600,000+ U.S. veterans found GLP-1 users had a 14% lower risk of developing any substance use disorder, with reductions seen across alcohol, opioids, nicotine, cocaine, and cannabis. Even patients who discontinued GLP-1s retained a 20% lower risk of repeat overdose.
Researchers believe the drugs may act on shared reward pathways in the brain — dampening cravings rather than targeting any one substance. GLP-1 receptors are present in brain regions tied to reward processing, and the drugs may modulate dopamine signaling, reduce neuroinflammation, and regulate impulse control. A separate safety study also confirmed GLP-1s are well-tolerated in people with opioid use disorder, with lower risks for pancreatitis, insomnia, and anxiety. Experts emphasize that while the signals are compelling, GLP-1s are not yet approved for addiction and should not replace established treatments — randomized controlled trials are still needed.
By the Numbers
Why it matters: GLP-1s are already in millions of hands — if trials confirm their anti-addiction effects, they could become the first cross-substance treatment for addiction, addressing a massive unmet need where current therapies are limited, underused, or nonexistent.
